Antiseizure medicines (ASMs) are one of the most commonly used teratogens. The current benchmarks include impact of epilepsy on women's health outcomes and health of their offspring (fetal and neonatal development, but progress is slow and the risks of fetal exposure for most ASMs remain unknown. Integrated basic and clinical research is needed to fully delineate risks and underlying mechanisms for ASM-induced anatomical and behavioral teratogenesis including new approaches such as systematic preclinical testing and evaluation of clinical populations, determination of genetic risk factors, and development of biomarkers and mitigating treatments.
Idea No. 104